What Should You Look for When Choosing a Pharmacogenomics Test?

Pharmacogenomics (PGx) testing is increasingly used to help guide medication choices based on an individual’s genetic profile. By analyzing genes involved in drug metabolism and drug response, pharmacogenomics testing can help explain why some medications work well for certain people while others experience reduced effectiveness or unwanted side effects.

As pharmacogenomics testing becomes more widely available through clinics, hospitals, and pharmacies, it is important for patients and healthcare professionals to understand that not all PGx tests are the same. The clinical value of a pharmacogenomics test depends on several important factors including the technology used, gene coverage, laboratory quality, interpretation framework, and external quality validation.

Before deciding on a pharmacogenomics test, here are several key aspects worth considering.

Technology Platform: Microarray vs Next-Generation Sequencing

One of the most important factors in pharmacogenomics testing is the technology platform used to analyze pharmacogenes.

Some tests rely on microarray technology, which detects a predefined set of genetic variants. While microarrays can identify common variants efficiently, they are limited to the variants included on the array. This means rare or newly discovered variants may not be detected.

More advanced pharmacogenomics tests use Next-Generation Sequencing (NGS). NGS reads larger sections of DNA and allows laboratories to detect a wider range of genetic variations within pharmacogenes. This broader detection capability makes NGS particularly useful for pharmacogenomics, where multiple variants across several genes may influence drug response.

NGS-based pharmacogenomics testing therefore provides more comprehensive genetic coverage and may offer greater long-term clinical value.

Coverage of Clinically Relevant Pharmacogenes

Another important consideration is which pharmacogenes are included in the test panel. Drug metabolism and drug response are influenced by several key genes that regulate how medications are processed in the body.

Some of the most clinically important pharmacogenes include:

• CYP2D6

• CYP2C19

• CYP2C9

• CYP3A4 / CYP3A5

• SLCO1B1

• VKORC1

• DPYD

• UGT1A1

These genes influence the metabolism or effectiveness of medications used in areas such as cardiovascular disease, psychiatry, pain management, oncology, and gastroenterology.

A pharmacogenomics test that covers a broader range of clinically relevant genes is more likely to provide useful insights whenever medications are prescribed in the future.

Evidence-Based Clinical Interpretation

A reliable pharmacogenomics test should interpret genetic findings based on internationally recognized clinical guidelines.

Organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), PharmGKB, and the Dutch Pharmacogenetics Working Group (DPWG) evaluate scientific evidence linking genetic variants with medication response. These organizations publish dosing recommendations and clinical guidance to help healthcare professionals apply pharmacogenomics information in clinical practice.

Using established interpretation frameworks ensures that pharmacogenomics results are not only scientifically valid but also clinically actionable.

Laboratory Accreditation and Quality Standards

The reliability of pharmacogenomics testing also depends heavily on the quality management systems of the laboratory performing the test.

Laboratories that operate under international standards such as ISO 15189 and CAP (College of American Pathologists) accreditation are required to maintain strict procedures for sample processing, quality control, sequencing accuracy, and result reporting.

These accreditations provide assurance that pharmacogenomics testing is performed under rigorous medical laboratory standards with validated workflows and ongoing quality monitoring.

Participation in International External Quality Assessment (EQA)

Another critical but often overlooked aspect of pharmacogenomics testing is participation in international External Quality Assessment (EQA) programs.

EQA programs allow laboratories to periodically test their performance by analyzing standardized samples provided by independent international organizations. The results are then compared with those from other laboratories worldwide to ensure consistency and accuracy.

Participation in recognized EQA schemes helps verify that a laboratory’s pharmacogenomics testing processes — including sequencing, variant detection, and interpretation — meet international benchmarks.

For patients and healthcare providers, EQA participation provides an additional layer of confidence that the laboratory’s testing performance is continuously monitored and validated against global standards.

Bioinformatics and Variant Interpretation

Generating genetic data is only part of pharmacogenomics testing. Accurate interpretation requires robust bioinformatics pipelines and curated pharmacogenomics databases.

High-quality pharmacogenomics testing relies on databases such as PharmGKB, ClinVar, and other curated genomic resources to determine whether specific variants are known to influence drug metabolism or drug response.

A strong bioinformatics infrastructure ensures that pharmacogenomic findings are interpreted accurately and updated as new scientific knowledge becomes available.

Clinical Guidance and Medication Management

Pharmacogenomics results are most useful when they can be translated into practical medication guidance.

Ideally, PGx testing should be supported by healthcare professionals such as pharmacists or clinicians trained in pharmacogenomics who can help interpret the results and incorporate them into medication management decisions.

This ensures that pharmacogenomics insights can be applied appropriately when medications are prescribed or adjusted.

Long-Term Value of Pharmacogenomics Testing

One unique advantage of pharmacogenomics testing is that genetic information remains constant throughout a person’s lifetime. Once pharmacogenes have been analyzed, the results may be referenced whenever medications are prescribed in the future.

Because of this long-term value, selecting a pharmacogenomics test that offers comprehensive coverage, reliable interpretation, and high laboratory quality standards is important to ensure the results remain useful for years to come.

---

Pharmacogenomics Testing with AGTC Genomics

AGTC Genomics offers PharmPGx™ Comprehensive Pharmacogenomics Testing, designed to provide clinically actionable insights into how individuals may respond to medications.

The test utilizes advanced Next-Generation Sequencing (NGS) technology to analyze key pharmacogenes involved in drug metabolism and drug response. Testing is performed in an ISO 15189 and CAP-accredited laboratory, supported by robust bioinformatics analysis and participation in international External Quality Assessment (EQA) programs to ensure testing accuracy and reliability.

PharmPGx™ is available through selected pharmacies, clinics, and hospitals nationwide, including Alpro Pharmacy. Individuals interested in pharmacogenomics testing are encouraged to speak with a pharmacist or healthcare professional to learn how genetic insights may help guide safer and more effective medication choices.